logo
ProjectFully Reimbursed

VACCINE DEVELOPMENT RDI (MGF)

The status, timeline and source of this project. A free account opens every field.

Source: European Investment Bank (EIB)

Valneva is a vaccine biotech company specialised in the development, manufacture and commercialisation of innovative vaccines. The company spends EUR 25-30m on R&D annually (equivalent to over 30% of revenues in 2015) and files on average 25 patents each year. The proposed operation would support Valneva's ongoing R&D efforts, and potentially enable the company to accelerate the development of its

Status
Closed
Sector
Manufacturing (Industrial), Government
Location
France
Updated
22 Jul 2026
Source
European Investment Bank (EIB)

ConstructChat

Ask ConstructChat about VACCINE DEVELOPMENT RDI (MGF)

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

4 Q
The project “VACCINE DEVELOPMENT RDI (MGF)” is an infrastructure initiative in the Manufacturing (Industrial) sector, located in France. Taiyo aggregates data on it from European Investment Bank (EIB).

Participants

Sponsoring Agency

Status

Original status

fully reimbursed

Taiyo status

Closed

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

Valneva is a vaccine biotech company specialised in the development, manufacture and commercialisation of innovative vaccines. The company spends EUR 25-30m on R&D annually (equivalent to over 30% of revenues in 2015) and files on average 25 patents each year. The proposed operation would support Valneva's ongoing R&D efforts, and potentially enable the company to accelerate the development of its lead product candidates, which target common diseases with no existing treatments or preventative m

Original sector

Industry

Location

Country

France

Source

Source

European Investment Bank (EIB)

URL

More Details

Record type

Project

Sector

Manufacturing (Industrial), Government

Article published date

2025-07-28

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project